Download PDF
Semin Respir Crit Care Med 2022; 43(02): 304-309
DOI: 10.1055/s-0041-1740583
Review Article

Methicillin-Resistant Staphylococcus aureus Hospital-Acquired Pneumonia/Ventilator-Associated Pneumonia

Chiagozie I. Pickens
1   Division of Critical Care, Department of Medicine, Pulmonary, Northwestern University Feinberg School of Medicine, Chicago, Illinois
,
Richard G. Wunderink
1   Division of Critical Care, Department of Medicine, Pulmonary, Northwestern University Feinberg School of Medicine, Chicago, Illinois
› Author Affiliations Funding This work is supported by NIH/NIAID grant U19AI135964.
› Further Information
    Permissions and Reprints

Abstract

Methicillin-resistant Staphylococcus aureus (MRSA) is a common cause of hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP). MRSA pneumonia is associated with significant morbidity and mortality. Several virulence factors allow S. aureus to become an effective pathogen. The polysaccharide intracellular adhesin allows for the production of biofilms, some strains can produce capsular polysaccharides that protect against phagocytosis, microbial surface components recognizing adhesive matrix molecules (MSCRAMMs) allow for colonization of epithelial surfaces, and S. aureus secretes several exotoxins that aid in tissue destruction. The α-hemolysin exotoxin secreted by S. aureus is one of the most important virulence factors for the bacteria. The diagnosis of MRSA pneumonia can be challenging; the infection may present as a mild respiratory infection or severe respiratory failure and septic shock. Many individuals are colonized with MRSA and thus a positive nasopharyngeal swab does not confirm infection in the lower respiratory tract. The management of MRSA pneumonia has evolved. Historically, vancomycin has been the primary antibiotic used to treat MRSA pneumonia. Over the past decade, prospective studies have shown that linezolid leads to higher rates of clinical cure. Monoclonal antibodies are being studied as potential therapeutic options. MRSA is an important cause of HAP/VAP; novel diagnostics may facilitate rapid diagnosis of this infection and the available literature should be used to make informed decisions on management.

Keywords

Methicillin-resistant Staphylococcus aureus - pneumonia - ventilator


Publication History

Article published online:
15 February 2022

© 2022. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Kollef MH, Shorr A, Tabak YP, Gupta V, Liu LZ, Johannes RS. Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia. Chest 2005; 128 (06) 3854-3862
    CrossrefPubMedGoogle Scholar
  • 2 Lee MS, Walker V, Chen LF, Sexton DJ, Anderson DJ. The epidemiology of ventilator-associated pneumonia in a network of community hospitals: a prospective multicenter study. Infect Control Hosp Epidemiol 2013; 34 (07) 657-662
    CrossrefPubMedGoogle Scholar
  • 3 Fridkin SK, Hill HA, Volkova NV. et al; Intensive Care Antimicrobial Resistance Epidemiology Project Hospitals. Temporal changes in prevalence of antimicrobial resistance in 23 US hospitals. Emerg Infect Dis 2002; 8 (07) 697-701
    CrossrefPubMedGoogle Scholar
  • 4 Lewis SS, Walker VJ, Lee MS. et al. Epidemiology of methicillin-resistant Staphylococcus aureus pneumonia in community hospitals. Infect Control Hosp Epidemiol 2014; 35 (12) 1452-1457
    CrossrefPubMedGoogle Scholar
  • 5 Dantes R, Mu Y, Belflower R. et al; Emerging Infections Program–Active Bacterial Core Surveillance MRSA Surveillance Investigators. National burden of invasive methicillin-resistant Staphylococcus aureus infections, United States, 2011. JAMA Intern Med 2013; 173 (21) 1970-1978
    PubMedGoogle Scholar
  • 6 Zahar J-R, Clec'h C, Tafflet M. et al; Outcomerea Study Group. Is methicillin resistance associated with a worse prognosis in Staphylococcus aureus ventilator-associated pneumonia?. Clin Infect Dis 2005; 41 (09) 1224-1231
    CrossrefPubMedGoogle Scholar
  • 7 Theaker C, Ormond-Walshe S, Azadian B, Soni N. MRSA in the critically ill. J Hosp Infect 2001; 48 (02) 98-102
    CrossrefPubMedGoogle Scholar
  • 8 DeRyke CA, Lodise Jr TP, Rybak MJ, McKinnon PS. Epidemiology, treatment, and outcomes of nosocomial bacteremic Staphylococcus aureus pneumonia. Chest 2005; 128 (03) 1414-1422
    CrossrefPubMedGoogle Scholar
  • 9 Shorr AF, Tabak YP, Gupta V, Johannes RS, Liu LZ, Kollef MH. Morbidity and cost burden of methicillin-resistant Staphylococcus aureus in early onset ventilator-associated pneumonia. Crit Care 2006; 10 (03) R97
    CrossrefPubMedGoogle Scholar
  • 10 Shorr AF, Combes A, Kollef MH, Chastre J. Methicillin-resistant Staphylococcus aureus prolongs intensive care unit stay in ventilator-associated pneumonia, despite initially appropriate antibiotic therapy. Crit Care Med 2006; 34 (03) 700-706
    CrossrefPubMedGoogle Scholar
  • 11 Kalil AC, Metersky ML, Klompas M. et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis 2016; 63 (05) e61-e111
    CrossrefPubMedGoogle Scholar
  • 12 Ekren PK, Ranzani OT, Ceccato A. et al. Evaluation of the 2016 Infectious Diseases Society of America/American Thoracic Society Guideline Criteria for risk of multidrug-resistant pathogens in patients with hospital-acquired and ventilator-associated pneumonia in the ICU. Am J Respir Crit Care Med 2018; 197 (06) 826-830
    CrossrefPubMedGoogle Scholar
  • 13 Jenkins A, Diep BA, Mai TT. et al. Differential expression and roles of Staphylococcus aureus virulence determinants during colonization and disease. MBio 2015; 6 (01) e02272-e14
    CrossrefPubMedGoogle Scholar
  • 14 Wertheim HF, Melles DC, Vos MC. et al. The role of nasal carriage in Staphylococcus aureus infections. Lancet Infect Dis 2005; 5 (12) 751-762
    CrossrefPubMedGoogle Scholar
  • 15 von Eiff C, Becker K, Machka K, Stammer H, Peters G. Study Group. Nasal carriage as a source of Staphylococcus aureus bacteremia. N Engl J Med 2001; 344 (01) 11-16
    CrossrefPubMedGoogle Scholar
  • 16 Stapleton PD, Taylor PW. Methicillin resistance in Staphylococcus aureus: mechanisms and modulation. Sci Prog 2002; 85 (Pt 1): 57-72
    CrossrefPubMedGoogle Scholar
  • 17 Chambers HF. Methicillin resistance in staphylococci: molecular and biochemical basis and clinical implications. Clin Microbiol Rev 1997; 10 (04) 781-791
    CrossrefPubMedGoogle Scholar
  • 18 Harkins CP, Pichon B, Doumith M. et al. Methicillin-resistant Staphylococcus aureus emerged long before the introduction of methicillin into clinical practice. Genome Biol 2017; 18 (01) 130-130
    CrossrefPubMedGoogle Scholar
  • 19 Gordon RJ, Lowy FD. Pathogenesis of methicillin-resistant Staphylococcus aureus infection. Clin Infect Dis 2008; 46 (05, Suppl 5): S350-S359
    CrossrefPubMedGoogle Scholar
  • 20 Verdier I, Durand G, Bes M. et al. Identification of the capsular polysaccharides in Staphylococcus aureus clinical isolates by PCR and agglutination tests. J Clin Microbiol 2007; 45 (03) 725-729
    CrossrefPubMedGoogle Scholar
  • 21 Parker D, Prince A. Immunopathogenesis of Staphylococcus aureus pulmonary infection. Semin Immunopathol 2012; 34 (02) 281-297
    CrossrefPubMedGoogle Scholar
  • 22 Foster TJ, Geoghegan JA, Ganesh VK, Höök M. Adhesion, invasion and evasion: the many functions of the surface proteins of Staphylococcus aureus . Nat Rev Microbiol 2014; 12 (01) 49-62
    CrossrefPubMedGoogle Scholar
  • 23 Tabor DE, Yu L, Mok H. et al. Staphylococcus aureus alpha-toxin is conserved among diverse hospital respiratory isolates collected from a global surveillance study and is neutralized by monoclonal antibody MEDI4893. Antimicrob Agents Chemother 2016; 60 (09) 5312-5321
    CrossrefPubMedGoogle Scholar
  • 24 Bhakdi S, Tranum-Jensen J. Alpha-toxin of Staphylococcus aureus . Microbiol Rev 1991; 55 (04) 733-751
    CrossrefPubMedGoogle Scholar
  • 25 Berube BJ, Bubeck Wardenburg J. Staphylococcus aureus α-toxin: nearly a century of intrigue. Toxins (Basel) 2013; 5 (06) 1140-1166
    CrossrefPubMedGoogle Scholar
  • 26 Bubeck Wardenburg J, Patel RJ, Schneewind O. Surface proteins and exotoxins are required for the pathogenesis of Staphylococcus aureus pneumonia. Infect Immun 2007; 75 (02) 1040-1044
    CrossrefPubMedGoogle Scholar
  • 27 Becker KA, Fahsel B, Kemper H. et al. Staphylococcus aureus alpha-toxin disrupts endothelial-cell tight junctions via acid sphingomyelinase and ceramide. Infect Immun 2017; 86 (01) e00606-17
    CrossrefPubMedGoogle Scholar
  • 28 Powers ME, Kim HK, Wang Y, Bubeck Wardenburg J. ADAM10 mediates vascular injury induced by Staphylococcus aureus α-hemolysin. J Infect Dis 2012; 206 (03) 352-356
    CrossrefPubMedGoogle Scholar
  • 29 Pettigrew MM, Tanner W, Harris AD. The lung microbiome and pneumonia. J Infect Dis 2021; 223 (12, Suppl 2): S241-S245
    CrossrefPubMedGoogle Scholar
  • 30 Clark SE. Commensal bacteria in the upper respiratory tract regulate susceptibility to infection. Curr Opin Immunol 2020; 66: 42-49
    CrossrefPubMedGoogle Scholar
  • 31 Levine SA, Niederman MS. The impact of tracheal intubation on host defenses and risks for nosocomial pneumonia. Clin Chest Med 1991; 12 (03) 523-543
    CrossrefPubMedGoogle Scholar
  • 32 Dangerfield B, Chung A, Webb B, Seville MT. Predictive value of methicillin-resistant Staphylococcus aureus (MRSA) nasal swab PCR assay for MRSA pneumonia. Antimicrob Agents Chemother 2014; 58 (02) 859-864
    CrossrefPubMedGoogle Scholar
  • 33 Paonessa JR, Shah RD, Pickens CI. et al. Rapid detection of methicillin-resistant Staphylococcus aureus in BAL: a pilot randomized controlled trial. Chest 2019; 155 (05) 999-1007
    CrossrefPubMedGoogle Scholar
  • 34 Fagon JY, Chastre J, Wolff M. et al. Invasive and noninvasive strategies for management of suspected ventilator-associated pneumonia. A randomized trial. Ann Intern Med 2000; 132 (08) 621-630
    CrossrefPubMedGoogle Scholar
  • 35 Torres A, Niederman MS, Chastre J. et al. International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: guidelines for the management of hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP) of the European Respiratory Society (ERS), European Society of Intensive Care Medicine (ESICM), European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and Asociación Latinoamericana del Tórax (ALAT). Eur Respir J 2017; 50 (03) 1700582
    CrossrefPubMedGoogle Scholar
  • 36 Cuny C, Witte W. PCR for the identification of methicillin-resistant Staphylococcus aureus (MRSA) strains using a single primer pair specific for SCCmec elements and the neighbouring chromosome-borne orfX. Clin Microbiol Infect 2005; 11 (10) 834-837
    CrossrefPubMedGoogle Scholar
  • 37 Cruciani M, Gatti G, Lazzarini L. et al. Penetration of vancomycin into human lung tissue. J Antimicrob Chemother 1996; 38 (05) 865-869
    CrossrefPubMedGoogle Scholar
  • 38 Stein GE, Wells EM. The importance of tissue penetration in achieving successful antimicrobial treatment of nosocomial pneumonia and complicated skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus: vancomycin and linezolid. Curr Med Res Opin 2010; 26 (03) 571-588
    CrossrefPubMedGoogle Scholar
  • 39 Wunderink RG, Niederman MS, Kollef MH. et al. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis 2012; 54 (05) 621-629
    CrossrefPubMedGoogle Scholar
  • 40 Peyrani P, Wiemken TL, Kelley R. et al; IMPACT-HAP Study Group. Higher clinical success in patients with ventilator-associated pneumonia due to methicillin-resistant Staphylococcus aureus treated with linezolid compared with vancomycin: results from the IMPACT-HAP study. Crit Care 2014; 18 (03) R118
    CrossrefPubMedGoogle Scholar
  • 41 Tong MC, Wisniewski CS, Wolf B, Bosso JA. Comparison of linezolid and vancomycin for methicillin-resistant Staphylococcus aureus pneumonia: institutional implications. Pharmacotherapy 2016; 36 (07) 731-739
    CrossrefPubMedGoogle Scholar
  • 42 Wunderink RG, Rello J, Cammarata SK, Croos-Dabrera RV, Kollef MH. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 2003; 124 (05) 1789-1797
    CrossrefPubMedGoogle Scholar
  • 43 Kato H, Hagihara M, Asai N. et al. Meta-analysis of vancomycin versus linezolid in pneumonia with proven methicillin-resistant Staphylococcus aureus . J Glob Antimicrob Resist 2021; 24: 98-105
    CrossrefPubMedGoogle Scholar
  • 44 Steven D. Burdette, Robin Trotman, Tedizolid: The First Once-Daily Oxazolidinone Class Antibiotic, Clinical Infectious Diseases. , Volume 61, Issue 8, 15 October 2015, Pages 1315–1321
    PubMedGoogle Scholar
  • 45 Richard GWunderink, Antoine Roquilly, Martin Croce, Daniel RodriguezGonzalez, Satoshi Fujimi, Joan RButterton, Natasha Broyde, Myra WPopejoy, Jason YKim, Carisa De Anda. A Phase 3, Randomized, Double-Blind Study Comparing Tedizolid Phosphate and Linezolid for Treatment of Ventilated Gram-Positive Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia, Clinical Infectious Diseases. , Volume 73, Issue 3, 1 August 2021, Pages e710–e718
    PubMedGoogle Scholar
  • 46 Casapao AM, Davis SL, Barr VO. et al. Large retrospective evaluation of the effectiveness and safety of ceftaroline fosamil therapy. Antimicrob Agents Chemother 2014; 58 (05) 2541-2546
    CrossrefPubMedGoogle Scholar
  • 47 Awad SS, Rodriguez AH, Chuang YC. et al. A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia. Clin Infect Dis 2014; 59 (01) 51-61
    CrossrefPubMedGoogle Scholar
  • 48 Palmer LB, Smaldone GC. Eradication of MRSA ventilator-associated infection with inhaled vancomycin. Eur Respir J 2017; 50 (Suppl. 61) OA4655
    PubMedGoogle Scholar
  • 49 Kiefer A, Bogdan C, Melichar VO. Successful eradication of newly acquired MRSA in six of seven patients with cystic fibrosis applying a short-term local and systemic antibiotic scheme. BMC Pulm Med 2018; 18 (01) 20
    CrossrefPubMedGoogle Scholar
  • 50 Speziale P, Rindi S, Pietrocola G. Antibody-based agents in the management of antibiotic-resistant Staphylococcus aureus diseases. Microorganisms 2018; 6 (01) 25
    CrossrefPubMedGoogle Scholar
  • 51 Rouha H, Badarau A, Visram ZC. et al. Five birds, one stone: neutralization of α-hemolysin and 4 bi-component leukocidins of Staphylococcus aureus with a single human monoclonal antibody. MAbs 2015; 7 (01) 243-254
    CrossrefPubMedGoogle Scholar
  • 52 François B, Mercier E, Gonzalez C. et al; MASTER 1 Study Group. Safety and tolerability of a single administration of AR-301, a human monoclonal antibody, in ICU patients with severe pneumonia caused by Staphylococcus aureus: first-in-human trial. Intensive Care Med 2018; 44 (11) 1787-1796
    CrossrefPubMedGoogle Scholar
  • 53 Wunderink RG. Turning the phage on treatment of antimicrobial-resistant pneumonia. Am J Respir Crit Care Med 2019; 200 (09) 1081-1082
    CrossrefPubMedGoogle Scholar
  • 54 Punjabi CD, Madaline T, Gendlina I, Chen V, Nori P, Pirofski L-A. Prevalence of methicillin-resistant Staphylococcus aureus (MRSA) in respiratory cultures and diagnostic performance of the MRSA nasal polymerase chain reaction (PCR) in patients hospitalized with coronavirus disease 2019 (COVID-19) pneumonia. Infect Control Hosp Epidemiol 2021; 42 (09) 1156-1158
    CrossrefPubMedGoogle Scholar
  • 55 Pickens CO, Gao CA, Cuttica M. et al. Bacterial superinfection pneumonia in SARS-CoV-2 respiratory failure. medRxiv 2021. Doi: 10.1101/2021.01.12.20248588
    PubMedGoogle Scholar
  • 56 McDanel JS, Perencevich EN, Storm J. et al. Increased mortality rates associated with Staphylococcus aureus and influenza co-infection, Maryland and Iowa, USA(1). Emerg Infect Dis 2016; 22 (07) 1253-1256
    CrossrefPubMedGoogle Scholar